Agreements reached under this partnership
Business alliance- 1
Grant of exclusive rights in the target markets relating to regulatory submissions, obtaining and maintaining approval for, and commercialising QUVIVIQ®
- 2
Synmosa will lead regulatory affairs, market access, marketing, distribution and sales in each country.
- 3
The Group will be responsible for supplying the product and providing the necessary regulatory support.
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
The impact on the Group’s consolidated results for the fiscal year ending December 2026 has already been incorporated into the consolidated earnings forecast for the current fiscal year disclosed on 13 February 2026. The Company believes this matter will contribute to higher business earnings and corporate value over the medium to long term.
| Item | Details |
|---|---|
| Name of alliance partner | Synmosa Biopharma Corporation |
| Alliance partner's business activities | The company is broadly engaged in the in-licensing, research and development, manufacturing and sale of pharmaceuticals. Based in Taiwan, it has established business and partnership networks in Hong Kong, China and other Asian countries, and has commercialisation capabilities covering regulatory affairs, market access, promotion, warehousing and logistics. |
| Alliance partner's location | Taiwan |
| Type of alliance | Business alliance |
| Details of the alliance | Grant of exclusive rights in the target markets relating to regulatory submissions, obtaining and maintaining approval for, and commercialising QUVIVIQ®, Synmosa will lead regulatory affairs, market access, marketing, distribution and sales in each country., The Group will be responsible for supplying the product and providing the necessary regulatory support. |
| Contract Date | 14 October 2026 |
| Impact on Business Performance | The impact on the Group’s consolidated results for the fiscal year ending December 2026 has already been incorporated into the consolidated earnings forecast for the current fiscal year disclosed on 13 February 2026. The Company believes this matter will contribute to higher business earnings and corporate value over the medium to long term. |
Items this document does not state (16)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To leverage Synmosa’s business platform, regulatory submission, market access, sales and distribution experience built up in the target markets to obtain approval for and commercialise QUVIVIQ®. The agreement also advances the strategy of expanding access to innovative specialty pharmaceuticals in Japan and the Asia-Pacific region.